Developing a new class of drugs for treatment of inflammation and cancer

Novakand Pharma is developing a new class of innovative drugs focusing on significant medical needs in inflammatory diseases and cancer.

Novakand Pharma initiates process to seek stakeholders for a reverse take over

Novakand Pharma has decided to initiate a process to seek potential stakeholders for a reverse take over of the company. The company assesses that the company’s listing at the Nasdaq First North Growth Market in Stockholm together with its cash may be of a significant value.

The decision was made after a review of the company’s strategic options showing significant difficulties in driving the business forward in the context of the continued challenging conditions in the capital markets.

Read more